← Back to directory
VV
Versant Ventures
San Francisco, CaliforniaWebsite ↗
Versant Ventures is a venture capital firm focused on healthcare and biotechnology investments, specializing in creating and nurturing innovative companies that leverage scientific advancements to develop novel therapeutics. The firm employs a dual investment strategy, allocating capital to both external investments and in-house company creation through its Discovery Engines.
Last raised
Jan 2023
3y 6mo ago
Latest fund size
$600M
Versant Venture Capital IX
AUM
$5.5B
estimated
Funds raised
Capital this firm has raised, newest first
Versant Venture Capital IX
Jan 2023 · Fund IX
$600M
Versant Venture Capital VIII
Apr 2021 · Fund VIII
$560M
Versant Voyageurs II
Apr 2021 · Voyageurs II
$140M
Versant Vantage II
Apr 2021 · Vantage II
$250M
Versant Venture Capital VII
Jan 2018 · Fund VII
$600M
Versant Venture Capital VI
Jan 2017 · Fund VI
$400M
Versant Venture Capital I
Jan 1999 · Fund I
$250M
Recent investments
Companies this firm has funded, newest first
| Company | Round | Amount | Date | Source |
|---|---|---|---|---|
| Dayra Therapeutics | Series C | — | Unknown | |
| AllRock Bio | — | — | Unknown | |
| Nexo Therapeutics | — | — | Unknown | |
| Saturnus Bio | Early Stage | — | Jun 2026 | |
| Granite Bio | — | $100M | Apr 2025 | |
| Helicore Biopharma | Early Stage | — | Jan 2025 | |
| Pep2Tango Therapeutics Inc. | — | — | Nov 2024 | |
| Bright Peak Therapeutics | — | $90M | Jun 2024 |
Sources
Where this data came from